Shopping Cart 0
Cart Subtotal
USD 0

Regulus Therapeutics Inc (RGLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its lead product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome; and RGLS4326, an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company's products are used in the therapeutic areas of hepatitis C infection, cardiovascular disease, cancer, fibrosis, immune inflammatory diseases and metabolic diseases, among others. Regulus Therapeutics. Regulus Therapeutics is headquartered in San Diego, California, the US.

Regulus Therapeutics Inc (RGLS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

STA Pharma and Regulus Therapeutics Enter into microRNA Development Agreement 12

Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 13

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 14

Licensing Agreements 15

Regulus Therapeutics Amends Licensing Agreement With Sanofi 15

Equity Offering 16

Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 16

Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 17

Regulus Therapeutics Raises USD82 Million in Public Offering of Shares 19

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 21

Regulus Therapeutics Completes Public Offering Of Shares For USD 49.2 Million 22

Regulus Announces Partial Exercise Of Underwriter's Option For IPO For USD 51 Million 24

Regulus Therapeutics Completes Private Placement Of Shares For USD 25 Million 26

Regulus Therapeutics Inc-Key Competitors 27

Regulus Therapeutics Inc-Key Employees 28

Regulus Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

Aug 09, 2018: Regulus Therapeutics reports second quarter 2018 financial results 30

May 10, 2018: Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress 32

Mar 07, 2018: Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update 33

Nov 07, 2017: Regulus Reports Third Quarter 2017 Financial Results and Recent Events 34

Aug 01, 2017: Regulus Reports Second Quarter 2017 Financial Results and Recent Events 35

May 04, 2017: Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring 36

Mar 02, 2017: Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update 37

Corporate Communications 39

Apr 17, 2018: Kathryn J. Collier Joins Regulus Board Of Directors 39

Jun 13, 2017: Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer 40

Jun 01, 2017: Pascale Witz Joins Regulus Board of Directors 41

Product News 42

Sep 26, 2018: Regulus Provides Pipeline Updates 42

06/12/2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326 43

02/16/2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD 44

Clinical Trials 45

Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RG-012 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Regulus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

STA Pharma and Regulus Therapeutics Enter into microRNA Development Agreement 12

Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 13

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 14

Regulus Therapeutics Amends Licensing Agreement With Sanofi 15

Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 16

Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 17

Regulus Therapeutics Raises USD82 Million in Public Offering of Shares 19

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 21

Regulus Therapeutics Completes Public Offering Of Shares For USD 49.2 Million 22

Regulus Announces Partial Exercise Of Underwriter's Option For IPO For USD 51 Million 24

Regulus Therapeutics Completes Private Placement Of Shares For USD 25 Million 26

Regulus Therapeutics Inc, Key Competitors 27

Regulus Therapeutics Inc, Key Employees 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Regulus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its lead product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome; and RGLS4326, an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company's products are used in the therapeutic areas of hepatitis C infection, cardiovascular disease, cancer, fibrosis, immune inflammatory diseases and metabolic diseases, among others. Regulus Therapeutics. Regulus Therapeutics is headquartered in San Diego, California, the US.

Regulus Therapeutics Inc (RGLS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

STA Pharma and Regulus Therapeutics Enter into microRNA Development Agreement 12

Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 13

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 14

Licensing Agreements 15

Regulus Therapeutics Amends Licensing Agreement With Sanofi 15

Equity Offering 16

Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 16

Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 17

Regulus Therapeutics Raises USD82 Million in Public Offering of Shares 19

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 21

Regulus Therapeutics Completes Public Offering Of Shares For USD 49.2 Million 22

Regulus Announces Partial Exercise Of Underwriter's Option For IPO For USD 51 Million 24

Regulus Therapeutics Completes Private Placement Of Shares For USD 25 Million 26

Regulus Therapeutics Inc-Key Competitors 27

Regulus Therapeutics Inc-Key Employees 28

Regulus Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

Aug 09, 2018: Regulus Therapeutics reports second quarter 2018 financial results 30

May 10, 2018: Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress 32

Mar 07, 2018: Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update 33

Nov 07, 2017: Regulus Reports Third Quarter 2017 Financial Results and Recent Events 34

Aug 01, 2017: Regulus Reports Second Quarter 2017 Financial Results and Recent Events 35

May 04, 2017: Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring 36

Mar 02, 2017: Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update 37

Corporate Communications 39

Apr 17, 2018: Kathryn J. Collier Joins Regulus Board Of Directors 39

Jun 13, 2017: Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer 40

Jun 01, 2017: Pascale Witz Joins Regulus Board of Directors 41

Product News 42

Sep 26, 2018: Regulus Provides Pipeline Updates 42

06/12/2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326 43

02/16/2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD 44

Clinical Trials 45

Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RG-012 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Regulus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

STA Pharma and Regulus Therapeutics Enter into microRNA Development Agreement 12

Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 13

Regulus Therapeutics Expands Agreement With Sanofi-Aventis 14

Regulus Therapeutics Amends Licensing Agreement With Sanofi 15

Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 16

Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 17

Regulus Therapeutics Raises USD82 Million in Public Offering of Shares 19

Regulus Therapeutics Completes Private Placement Of Shares For USD 10 Million 21

Regulus Therapeutics Completes Public Offering Of Shares For USD 49.2 Million 22

Regulus Announces Partial Exercise Of Underwriter's Option For IPO For USD 51 Million 24

Regulus Therapeutics Completes Private Placement Of Shares For USD 25 Million 26

Regulus Therapeutics Inc, Key Competitors 27

Regulus Therapeutics Inc, Key Employees 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Regulus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.